Bauer D C, Hunter D J, Abramson S B, Attur M, Corr M, Felson D, Heinegård D, Jordan J M, Kepler T B, Lane N E, Saxne T, Tyree B, Kraus V B
Department of Medicine, University of California, San Francisco, CA 94107, USA.
Osteoarthritis Cartilage. 2006 Aug;14(8):723-7. doi: 10.1016/j.joca.2006.04.001. Epub 2006 Jun 2.
Osteoarthritis (OA) biomarkers are needed by researchers and clinicians to assist in disease diagnosis and assessment of disease severity, risk of onset, and progression. As effective agents for OA are developed and tested in clinical studies, biomarkers that reliably mirror or predict the progression or amelioration of OA will also be needed.
The NIH-funded OA Biomarkers Network is a multidisciplinary group interested in the development and validation of OA biomarkers. This review summarizes our efforts to characterize and classify OA biomarkers.
We propose the "BIPED" biomarker classification (which stands for Burden of Disease, Investigative, Prognostic, Efficacy of Intervention and Diagnostic), and offer suggestions on optimal study design and analytic methods for use in OA investigations.
The BIPED classification provides specific biomarker definitions with the goal of improving our ability to develop and analyze OA biomarkers, and to communicate these advances within a common framework.
研究人员和临床医生需要骨关节炎（OA）生物标志物来辅助疾病诊断、评估疾病严重程度、发病风险和病情进展。随着有效的OA治疗药物在临床研究中得到开发和测试，还将需要能够可靠反映或预测OA病情进展或改善情况的生物标志物。
由美国国立卫生研究院资助的OA生物标志物网络是一个多学科团队，致力于OA生物标志物的开发和验证。本综述总结了我们在OA生物标志物特征描述和分类方面所做的工作。
我们提出了“BIPED”生物标志物分类法（代表疾病负担、调查、预后、干预效果和诊断），并就OA研究中最佳研究设计和分析方法提供了建议。
BIPED分类法提供了具体的生物标志物定义，目的是提高我们开发和分析OA生物标志物的能力，并在一个通用框架内交流这些进展。
